The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma

被引:62
|
作者
Simon, Bianca [1 ,2 ]
Wiesinger, Manuel [1 ]
Maerz, Johannes [1 ]
Wistuba-Hamprecht, Kilian [3 ]
Weide, Benjamin [3 ]
Schuler-Thurner, Beatrice [1 ]
Schuler, Gerold [1 ]
Doerrie, Jan [1 ]
Uslu, Ugur [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Dermatol, D-91054 Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Div Genet, Dept Biol, D-91058 Erlangen, Germany
[3] Eberhard Karls Univ Tubingen, Univ Med Ctr, Dept Dermatol, D-72076 Tubingen, Germany
关键词
cancer; human; adoptive T-cell therapy; chimeric antigen receptor; T-cell receptor; immune escape; T cells; NKT cells; CHIMERIC-ANTIGEN RECEPTOR; INVARIANT NKT CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; MESSENGER-RNA; ANTITUMOR-ACTIVITY; DENDRITIC CELLS; PHASE-I; ACTIVATION; EXPANSION; LEUKEMIA;
D O I
10.3390/ijms19082365
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Natural killer T (NKT) cells represent a cell subpopulation that combines characteristics of natural killer (NK) cells and T cells. Through their endogenous T-cell receptors (TCRs), they reveal a pronounced intrinsic anti-tumor activity. Thus, a NKT cell transfected with a chimeric antigen receptor (CAR), which recognizes a tumor-specific surface antigen, could attack tumor cells antigen-specifically via the CAR and additionally through its endogenous TCR. NKT cells were isolated from peripheral blood mononuclear cells (PBMCs), expanded, and electroporated with mRNA encoding a chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR. The CAR expression on NKT cells and their in vitro functionality were analyzed. A transfection efficiency of more than 80% was achieved. Upon stimulation with melanoma cells, CAR-NKT cells produced cytokines antigen-specifically. Compared with conventional CAR-T cells, cytokine secretion of CAR-NKT cells was generally lower. Specific cytotoxicity, however, was similar with CAR-NKT cells showing a trend towards improved cytotoxicity. Additionally, CAR-NKT cells could kill target cells through their endogenous TCRs. In summary, it is feasible to generate CAR-NKT cells by using mRNA electroporation. Their CAR-mediated cytotoxicity is at least equal to that of conventional CAR-T cells, while their intrinsic cytotoxic activity is maintained. Thus, CAR-NKT cells may represent a valuable alternative to conventional CAR-T cells for cancer immunotherapy.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Antibody-targeted T cells and natural killer cells for cancer immunotherapy
    Sutherland, Ashley R.
    Parlekar, Brijesh
    Livingstone, David W.
    Medina, Andres X.
    Bernhard, Wendy
    Garcia, Tays Hernandez
    DeCoteau, John
    Geyer, C. Ronald
    JOURNAL OF NANOBIOTECHNOLOGY, 2024, 22 (01)
  • [32] Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
    Bedard, Melissa
    Salio, Mariolina
    Cerundolo, Vincenzo
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [33] Natural Killer Cells in Cancer Immunotherapy
    Miller, Jeffrey S.
    Lanier, Lewis L.
    ANNUAL REVIEW OF CANCER BIOLOGY, VOL 3, 2019, 3 : 77 - 103
  • [34] Natural killer cells in tumor immunotherapy
    Wang, Dongyao
    Wei, Haiming
    CANCER BIOLOGY & MEDICINE, 2023, 20 (08) : 539 - 544
  • [35] Natural killer cells in cancer immunotherapy
    Wang, DanRu
    Dou, LingYun
    Sui, LiHao
    Xue, Yiquan
    Xu, Sheng
    MEDCOMM, 2024, 5 (07):
  • [36] Cancer immunotherapy with natural killer cells
    Herberman, RB
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 27 - 30
  • [37] Natural killer cells in tumor immunotherapy
    Dongyao Wang
    Haiming Wei
    Cancer Biology & Medicine, 2023, 20 (08) : 539 - 544
  • [38] Natural killer cells in tumor immunotherapy
    Dongyao Wang
    Haiming Wei
    Cancer Biology & Medicine, 2023, (08) : 539 - 544
  • [39] Biomaterials promote in vivo generation and immunotherapy of CAR-T cells
    Qin, Ya-Ting
    Li, Ya-Ping
    He, Xi-Wen
    Wang, Xi
    Li, Wen-You
    Zhang, Yu-Kui
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
    Ibarrondo, F. Javier
    Yang, Otto O.
    Chodon, Thinle
    Avramis, Earl
    Lee, Yohan
    Sazegar, Hooman
    Jalil, Jason
    Chmielowski, Bartosz
    Koya, Richard C.
    Schmid, Ingrid
    Gomez-Navarro, Jesus
    Jamieson, Beth D.
    Ribas, Antoni
    Comin-Anduix, Begon A.
    PLOS ONE, 2013, 8 (10):